- Home
- RFI vs ABSI Comparison
RFI vs ABSI Comparison
Compare RFI & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFI
- ABSI
- Stock Information
- Founded
- RFI 1992
- ABSI 2011
- Country
- RFI United States
- ABSI United States
- Employees
- RFI N/A
- ABSI N/A
- Industry
- RFI Investment Managers
- ABSI Biotechnology: Pharmaceutical Preparations
- Sector
- RFI Finance
- ABSI Health Care
- Exchange
- RFI Nasdaq
- ABSI Nasdaq
- Market Cap
- RFI 321.0M
- ABSI 318.2M
- IPO Year
- RFI N/A
- ABSI 2021
- Fundamental
- Price
- RFI $11.79
- ABSI $3.14
- Analyst Decision
- RFI
- ABSI Strong Buy
- Analyst Count
- RFI 0
- ABSI 7
- Target Price
- RFI N/A
- ABSI $8.57
- AVG Volume (30 Days)
- RFI 69.8K
- ABSI 5.0M
- Earning Date
- RFI 01-01-0001
- ABSI 03-18-2025
- Dividend Yield
- RFI 8.25%
- ABSI N/A
- EPS Growth
- RFI N/A
- ABSI N/A
- EPS
- RFI N/A
- ABSI N/A
- Revenue
- RFI N/A
- ABSI $4,207,000.00
- Revenue This Year
- RFI N/A
- ABSI $7.92
- Revenue Next Year
- RFI N/A
- ABSI $162.34
- P/E Ratio
- RFI N/A
- ABSI N/A
- Revenue Growth
- RFI N/A
- ABSI N/A
- 52 Week Low
- RFI $9.62
- ABSI $2.45
- 52 Week High
- RFI $12.52
- ABSI $6.72
- Technical
- Relative Strength Index (RSI)
- RFI 39.29
- ABSI 39.74
- Support Level
- RFI $11.61
- ABSI $2.90
- Resistance Level
- RFI $12.52
- ABSI $3.26
- Average True Range (ATR)
- RFI 0.19
- ABSI 0.31
- MACD
- RFI -0.07
- ABSI -0.12
- Stochastic Oscillator
- RFI 19.78
- ABSI 17.74
About RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.